Loading clinical trials...
Loading clinical trials...
Venetoclax Combined With Azacytidine as Maintenance Therapy Post Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Conditions
Interventions
Venetoclax combined with Azacytidine
Start Date
September 1, 2024
Primary Completion Date
September 1, 2030
Completion Date
September 1, 2030
Last Updated
October 1, 2024
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06994676
NCT06484062
Lead Sponsor
Navy General Hospital, Beijing
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions